Compare KORE & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KORE | NSPR |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | 539 | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.6M | 72.1M |
| IPO Year | N/A | 2009 |
| Metric | KORE | NSPR |
|---|---|---|
| Price | $9.14 | $1.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $5.00 | $4.00 |
| AVG Volume (30 Days) | 43.4K | ★ 49.0K |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,310,000.00 |
| Revenue This Year | $8.96 | $57.98 |
| Revenue Next Year | N/A | $95.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.00 | $1.12 |
| 52 Week High | $9.19 | $2.93 |
| Indicator | KORE | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 73.77 | 26.43 |
| Support Level | $4.10 | N/A |
| Resistance Level | N/A | $2.47 |
| Average True Range (ATR) | 0.04 | 0.09 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 37.50 | 20.00 |
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates the majority of its revenue from the United States and the rest from other countries.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.